NCT07297589RecruitingPhase 3
Epicardial Cardiac Fat-CT (EPIC-CT)
Epicardial Cardiac Fat Comparative Trial
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
Both globally and nationally, heart disease remains the leading cause of death overall and across genders, with ischemic heart disease being the primary cause. It is now understood that multiple risk factors contribute to the development of this condition, notably type 2 diabetes mellitus and obesity, especially an increase in visceral fat. Among these, the role of epicardial fat volume in the presence of atheromatous plaques in patients with coronary artery disease has been emphasized, along with the link between its volume and the risk of ischemic cardiovascular events. Consequently, recent decades have seen focused research on the potential of epicardial fat as a marker for major adverse cardiac events and on strategies to reduce its volume as a treatment goal for patients with risk factors. Selective sodium-glucose cotransporter 2 inhibitors are drugs that, beyond their antihyperglycemic effect, have demonstrated cardiovascular benefits through various mechanisms, including a reduction in epicardial fat. This was supported by a previous study conducted by our research group, although no statistically significant difference was found. On the other hand, GLP-1 agonists are effective drugs for weight control in patients with severe obesity. However, little research has been done on their effect on more localized fat, such as epicardial fat.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- First submitted
- 9 Dec 2025
- Start date
- 30 Dec 2025
- Primary completion date
- Jan 2027
- Lead sponsor
- Instituto Mexicano del Seguro Social
- Diseases
- Coronary artery disease
- NCT number
- NCT07297589
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 136
- From 30 Dec 2025 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have recently received immunosuppressive therapy
- Use of any of the study drugs more than 6 months prior to randomization
Other illness
- Patients with a history of ischemic heart disease
- Known allergy to any of the medications used
- Patients with a history or current diagnosis of cancer
- Patients with documented active infections, such as pneumonia or urinary tract infections
Other
- Patients experiencing diabetic ketoacidosis
- Patients with hemodynamic instability (mean arterial pressure \<60 mmHg while on vasopressors)
- Pregnant women
- Patients with pancreatitis
Who the study is looking for
- Criteria for the fourth definition of acute myocardial infarction with and without ST-segment elevation.
- Diagnosed with type 2 diabetes.
- Initial serum high-sensitivity CRP value \> 2.0 mg/L.
- Clinically obese.
- LVEF \>50%.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Unidad Medica de Alta Especialidad No. 1, Bajío Coordinator of this site? Confirm its status | León | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.